 | |
 | |
| Clinical data | |
|---|---|
| Pronunciation | /ˌsɛftraɪˈæksoʊn/ |
| Trade names | Rocephin, Epicephin, Wintriaxone, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a685032 |
| License data | |
| Pregnancy category | |
| Routes of administration | Intravenous,intramuscular |
| Drug class | Third-generation cephalosporin |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Metabolism | Negligible |
| Eliminationhalf-life | 5.8–8.7 hours[3] |
| Excretion | 33–67%kidney, 35–45%biliary |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.070.347 |
| Chemical and physical data | |
| Formula | C18H18N8O7S3 |
| Molar mass | 554.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ceftriaxone, sold under the brand nameRocephin, is a third-generationcephalosporin antibiotic used for the treatment of a number ofbacterial infections.[4] These includemiddle ear infections,endocarditis,meningitis,pneumonia, bone and joint infections, intra-abdominal infections, skin infections,urinary tract infections,gonorrhea, andpelvic inflammatory disease.[4] It is also sometimes used before surgery and following abite wound to try to prevent infection.[4] Ceftriaxone can be given byinjection into a vein orinto a muscle.[4]
Common side effects include pain at the site of injection andallergic reactions.[4] Other possible side effects includeC. difficile-associated diarrhea,hemolytic anemia,gall bladder disease, andseizures.[4] It is not recommended in those who have hadanaphylaxis topenicillin but may be used in those who have had milder reactions.[4] The intravenous form should not be given with intravenouscalcium.[4] There is tentative evidence that ceftriaxone is relatively safe during pregnancy and breastfeeding.[1] It is athird-generation cephalosporin that works by preventing bacteria from making acell wall.[4]
Ceftriaxone was patented in 1978 and approved for medical use in 1982.[5] It is on theWorld Health Organization's List of Essential Medicines.[6] It is available as ageneric medication.[4]
Ceftriaxone and other third-generation cephalosporin antibiotics are used to treat organisms that tend to be resistant to many other antibiotics.[7] Due to emergent resistance, ceftriaxone should not be used for the treatment ofEnterobacter infections.[7] Before using ceftriaxone, it is important to determine the susceptibility of the bacteria.[8] If sepsis is being considered, empiric therapy may be initiated prior to susceptibility testing.[7]
Medical uses include:[8]
Ceftriaxone is also a choice drug for treatment ofbacterial meningitis caused bypneumococci,meningococci,Haemophilus influenzae, and "susceptible enteric Gram-negative rods, but notListeria monocytogenes."[9]
In combination withdoxycycline orazithromycin, ceftriaxone used to be recommended by the United StatesCenters for Disease Control and Prevention (CDC) for the treatment of uncomplicatedgonorrhea. Due to increased risk of developing azithromycin resistant strains and the high efficacy of higher doses of ceftriaxone the guidance has been updated to mono-antibiotic therapy with a higher dose of ceftriaxone.[10]
Like other third-generation cephalosporins, ceftriaxone is active againstCitrobacter spp.,Serratia marcescens, and beta-lactamase-producing strains ofHaemophilus andNeisseria.[7] However, unlikeceftazidime andcefoperazone, ceftriaxone does not have useful activity againstPseudomonas aeruginosa.[7] It is generally not active againstEnterobacter species, and its use should be avoided in the treatment ofEnterobacter infections, even if the isolate appears susceptible, because of the emergence of resistance.[7] Some organisms, such asCitrobacter,Providencia, andSerratia, have the ability to become resistant through the development ofcephalosporinases (enzymes thathydrolyze cephalosporins and render them inactive).[7]Although not being used as first line therapy againstStaphylococcus aureus, ceftriaxone retains activity against isolates of methicillin-susceptibleS. aureus and is used in clinic for infections sustained by this bacterium. In this case the dose should be doubled (e.g. 2 g intravenously every 12 hours).[11]
Ceftriaxone is available for administration via theintramuscular or theintravenous routes.[8] Ceftriaxone is stored as a dry powder in a vial, and is reconstituted (dissolved) immediately before use. The solution is used promptly after preparation, still, reconstituted solutions retain their physical and chemical stability for 24 hours at 25°C (or for 3 days when stored between 2 and 8°C).[12] The solutions are pale yellowish in color,[12] but the change of color to amber or reddish suggests hydrolysis of theamide bond of the β-lactam ring, thereby affecting the antimicrobial activity of the antibiotic.[13] Diluents containing calcium are not used to reconstitute ceftriaxone, and it must not be administered in intravenous lines containing other calcium-containing solutions, as a ceftriaxone-calcium precipitate could form.[8][14] This precipitation risk is particularly high in newborns (up to age 28 days), especially if they are premature or have impaired bilirubin binding.[15][16]
Ceftriaxone is pregnancy category B[clarification needed].[8][1] It has not been observed to cause birth defects in animal studies, but a lack of well-controlled studies done in pregnant women exists.[8]
Low concentrations of ceftriaxone are excreted inbreast milk that are "not expected to cause adverse effects in breastfed infants."[17][failed verification] The manufacturer recommends that caution be exercised when administering ceftriaxone to women who breastfeed.[8]
Hyperbilirubinemicneonates are contraindicated for the use of ceftriaxone.[8] It can compete withbilirubin and displace it from binding toalbumin, increasing the risk of bilirubinencephalopathy.[8]
According to the package insert, clinical studies did notshow differences in efficacy and safety of ceftriaxone in geriatrics compared to younger patients but "greater sensitivity of some older individuals cannot be ruled out."[8]
Although generally well tolerated, the most common adverse reactions associated with ceftriaxone are changes in white blood cell counts, local reactions at site of administration, rash, and diarrhea.[18]
Incidence of adverse effects greater than 1%:
Some less frequently reported adverse events (incidence < 1%) includephlebitis, itchiness, fever, chills, nausea, vomiting, elevations ofbilirubin, elevations increatinine, headache and dizziness.[18]
Ceftriaxone may precipitate in bile, causingbiliary sludge,biliary pseudolithiasis, andgallstones, especially in children.Hypoprothrombinaemia and bleeding are specific side effects. Haemolysis is reported.[19][20][21] It has also been reported to cause post kidney failure in children.[22] Like other antibiotics, ceftriaxone use can result inClostridioides difficile-associated diarrhea ranging from mild diarrhea to fatal colitis.[18] In this regard it has been reported that shifting from ceftriaxone tocefotaxime would have a lower impact onC. difficile infection rates, since cefotaxime is almost entirely excreted by the kidneys[23] while ceftriaxone has a 45% biliary excretion[24]
Ceftriaxone should not be used in those with an allergy to ceftriaxone or any component of the formulation. Although there is negligible cross-reactivity between penicillins and third-generation cephalosporins,[9][25] caution should still be used when using ceftriaxone in penicillin-sensitive patients.[18] Caution should be used in people who have had previous severe penicillin allergies.[18] It should not be used in hyperbilirubinemic neonates, particularly those who are premature because ceftriaxone is reported to displace bilirubin from albumin binding sites, potentially causing bilirubin encephalopathy. Concomitant use with intravenous calcium-containing solutions/products in neonates (≤28 days) is contraindicated[26] even if administered through different infusion lines due to rare fatal cases of calcium-ceftriaxone precipitations in neonatal lungs and kidneys.[18][27]
Ceftriaxone is a third-generation antibiotic from thecephalosporin family of antibiotics.[7] It is within theβ-lactam family of antibiotics. Ceftriaxone selectively and irreversibly inhibits bacterial cell wall synthesis by binding to transpeptidases, also called transamidases, which arepenicillin-binding proteins (PBPs) that catalyze the cross-linking of thepeptidoglycan polymers forming the bacterial cell wall.[28] The peptidoglycan cell wall is made up of pentapeptide units attached to a polysaccharide backbone with alternating units of N-acetylglucosamine and N-acetylmuramic acid.[29][30] PBPs act on a terminal D-alanyl-D-alanine moiety on a pentapeptide unit and catalyze the formation of a peptide bond between the penultimate D-alanine and a glycine unit on an adjacent peptidoglycan strand, releasing the terminal D-alanine unit in the process.[28][30] The structure of ceftriaxone mimics the D-alanyl-D-alanine moiety, and the PBP attacks the beta-lactam ring in ceftriaxone as if it were its normal D-alanyl-D-alanine substrate.[28] Thepeptidoglycan cross-linking activity of PBPs is a construction and repair mechanism that normally helps to maintain bacterial cell wall integrity, so the inhibition of PBPs leads to damage and destruction of the cell wall and eventually to cell lysis.[28]
Absorption: Ceftriaxone can be administered intravenously and intramuscularly, and the drug is completely absorbed.[8][31] It is not available orally.[32][33]
Distribution: Ceftriaxone penetrates tissues and body fluids well, includingcerebrospinal fluid to treat central nervous system infections.[8][34] Ceftriaxone is reversibly bound to human plasma proteins and the binding of ceftriaxone decreases with increasing concentration from a value of 95% at plasma concentrations less than 25 mcg/mL to 85% at plasma concentration of 300 mcg/mL. Over a 0.15 to 3 g dose range in healthy adult subjects, the apparentvolume of distribution ranged from 5.8 to 13.5 L.[8]
Metabolism: 33–67% of ceftriaxone is renally excreted as unchanged drug, but no dose adjustments are required in renal impairment with dosages up to 2 grams per day.[8] The rest[35] is excreted in the bile as unchanged drug[36] which is ultimately excreted in feces as inactive compounds from hepatic and gut flora metabolism.[8][37][38]
Elimination: The average elimination half-life in healthy adults is 5.8–8.7 (mean 6.5) hours,[3] with some reviews estimated half-life is up to 10 hours.[39] In people with renal impairment, the average elimination half-life increases to 11.4–15.7 hours.[8]
Ceftriaxone is commercially available as a white to yellowish-orange crystalline powder for reconstitution.[8] Reconstituted ceftriaxone injection solutions are light yellow- to amber-colored depending on how long the solution had been reconstituted, the concentration of ceftriaxone in the solution, and the diluent used.[8] To reduce pain with intramuscular injections, ceftriaxone may be reconstituted withlidocaine.[40]
Thesyn-configuration of themethoxyoxime moiety confers resistance tobeta-lactamase enzymes produced by manyGram-negative bacteria.[28] The stability of this configuration results in increased activity of ceftriaxone against otherwise resistant Gram-negative bacteria.[28] In place of the easilyhydrolyzedacetyl group of cefotaxime, ceftriaxone has a metabolically stable thiotriazinedione moiety.[28]
Ceftriaxone has also been investigated for efficacy in preventing relapse to cocaine addiction.[41]
Ceftriaxone seems to increaseexcitatory amino acid transporter-2 pump expression and activity in the central nervous system, so has a potential to reduce glutamatergic toxicity.[42][43]
Ceftriaxone has been shown to have neuroprotective properties in a number of neurological disorders, includingspinal muscular atrophy[44] andamyotrophic lateral sclerosis (ALS).[45] Despite earlier negative results in the 1990s, a large clinical trial was undertaken in 2006 to test ceftriaxone in ALS patients, but was stopped early after it became clear that the results would not meet the predetermined criteria for efficacy.[46]
